Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
Japanese regulators have compiled the results of a cost-effectiveness assessment (CEA) for Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide). The diabetes drug is expected to maintain its NHI price tag as the company’s appeal looking at a potential raise…
To read the full story
Related Article
- Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
November 17, 2025
- Xocova Price to Be Trimmed by 300 Yen after CEA; No Change for Mounjaro
November 14, 2024
REGULATORY
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
- MHLW Seeks 20.6 Billion Yen for MCM Stockpiles, Revenue Guarantees
September 14, 2026
- Atopic Dermatitis Proactive Therapy to Be Exempt from OTC-Like Drug Charge
September 14, 2026
- MFN Now a Factor in Japan’s Drug Pricing Debate: New Pharma Policy Chief
September 11, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…